Iyoke Chukwuemeka Anthony, Emegoakor Fausta Chioma, Ezugwu Euzebus Chinonye, Lawani Lucky Osaheni, Ajah Leonard Ogbonna, Madu Jude Anazoeze, Ezegwui Hyginus Uzo, Ezugwu Frank Okechukwu
Department of Obstetrics and Gynaecology, University of Nigeria, Enugu Campus.
Department of Obstetrics and Gynaecology, Federal Teaching Hospital, Abakaliki.
Ther Clin Risk Manag. 2017 May 17;13:647-653. doi: 10.2147/TCRM.S112227. eCollection 2017.
Iron-deficiency anemia is the most common nutritional cause of anemia in pregnancy and is often responsible for puerperal anemia. Puerperal anemia can impair postpartum maternal and neonatal well-being.
To determine the effect of treatment of moderate puerperal iron-deficiency anemia using a single intravenous total-dose iron dextran versus daily single dose oral iron(III)-hydroxide polymaltose.
A randomized controlled study in which postpartum women with moderate iron-deficiency anemia were randomized into treatment with either a single total-dose intravenous iron dextran or with daily single doses of oral iron(III)-hydroxide polymaltose tablets for 6 weeks. Effects on hemoglobin concentration using either method were compared at 6 weeks postpartum. Analysis was per protocol using SPSS version 17 for windows. -values ≤0.05 were considered significant.
Two hundred eighty-four women were recruited for the study: 142 women received single total dose intravenous infusion of iron dextran while 142 received daily oral iron(III)-hydroxide polymaltose tablets. Approximately 84.0% (237/282) completed the study and were analyzed including 81% (115/142) of those randomized to injectable iron therapy compared to 85.9% (122/142) of those randomized to oral treatment. The proportions of women who had attained hemoglobin concentration of at least 10 g/dL by the 6 weeks postpartum visit did not differ significantly between cases and controls (95.7% vs 94.3%; =0.73). Similarly, the mean increases in hemoglobin following either therapeutic route were comparable (1.03±0.56 g/dL for intravenous iron and 0.97±0.46 g/dL for the oral group; =0.42).
Single total-dose intravenous iron for treatment of puerperal iron-deficiency anemia was as effective as daily single doses of ferric iron tablets. For puerperal patients with iron-deficiency anemia in whom compliance with and tolerability of oral iron are not certain, a single total-dose intravenous iron can be safely offered.
缺铁性贫血是孕期最常见的营养性贫血病因，常导致产褥期贫血。产褥期贫血会损害产后母婴健康。
确定单次静脉注射总剂量右旋糖酐铁与每日单次口服氢氧化铁聚麦芽糖治疗中度产褥期缺铁性贫血的效果。
一项随机对照研究，将产后中度缺铁性贫血妇女随机分为两组，一组接受单次总剂量静脉注射右旋糖酐铁治疗，另一组接受每日单次口服氢氧化铁聚麦芽糖片治疗，为期6周。比较产后6周时两种治疗方法对血红蛋白浓度的影响。使用适用于Windows的SPSS 17版本按方案进行分析。P值≤0.05被认为具有统计学意义。
284名妇女被纳入研究：142名妇女接受单次总剂量静脉输注右旋糖酐铁，142名妇女接受每日口服氢氧化铁聚麦芽糖片。约84.0%（237/282）完成研究并接受分析，其中随机接受注射用铁剂治疗的患者中有81%（115/142），随机接受口服治疗的患者中有85.9%（122/142）。产后6周访视时血红蛋白浓度至少达到10 g/dL的妇女比例在病例组和对照组之间无显著差异（95.7%对94.3%；P = 0.73）。同样，两种治疗途径后血红蛋白的平均升高幅度相当（静脉注射铁剂组为1.03±0.56 g/dL，口服组为0.97±0.46 g/dL；P = 0.42）。
单次总剂量静脉注射铁剂治疗产褥期缺铁性贫血与每日单次口服铁剂片效果相同。对于口服铁剂的依从性和耐受性不确定的产褥期缺铁性贫血患者，可以安全地给予单次总剂量静脉注射铁剂。
Zotero 插件